In comparison to the 47 carriers of Cys-altering SNVs in EGFr 7–34 (amino acids 274–1373), the 6 carriers of Cys-altering SNVs in EGFr 1–6 (amino acids 40–272) exhibited more severe cerebral small vessel disease (CSVD) burden, including increased load of deep white matter hyperintensity (DWMH) lesions, periventricular hyperintensity (PVH) lesions, hyperintensity in the temporal lobe and external capsule, lacunes, microbleeds, and brain atrophy. Here, EGFR is linked to cerebral small vessel disease.